Patients Deep Dive: Patients & Partnerships 2024 IN THIS ISSUE: The 2024 US Presidential race is nearing its end, but what does that mean for pharma?
News Regeneron swoops on genetic testing firm 23andMe DNA testing company 23andMe looks destined to be taken over by a pharma company, as Regeneron agrees a $256 million acquisition deal.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
